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SUMMARY Uremic pruritus is still a common phenomenon in pa-
tients with end-stage renal failure, however, there is no effective 
treatment of choice for this condition.This study was undertaken 
to evaluate the efﬁcacy and tolerance of the cream with structured 
physiological lipids (DMS®, Derma Membrane Structure®) and en-
dogenous cannabinoids in controlling pruritus in patients on main-
tenance hemodialysis. Twenty-one subjects with uremic pruritus 
completed the trial. All patients applied the tested cream twice daily 
for a period of three weeks. Pruritus was evaluated using two pru-
ritus scoring methods: standard visual analog scale (VAS) and a 
questionnaire method. Moreover, all patients had dry skin scored 
according to the 5-point scale. Global pruritus and xerosis were 
examined before the trial, on study visits at weekly intervals, and on 
follow-up visit performed two weeks of study discontinuation.
After 3-week therapy pruritus was completely eliminated in 8 
(38.1%) patients. Pruritus evaluation by both scales revealed sig-
niﬁcant reduction of pruritus scores (p<0.0001) during the tested 
product application. At the beginning of the trial there was no sig-
niﬁcant correlation between the intensity of dry skin and severity 
of pruritus. The 3-week treatment period resulted in complete re-
duction of xerosis in 17 (81%) patients, while xerosis scores were 
signiﬁcantly reduced (p=0.0001) throughout the study period. The 
test product was very well tolerated by all patients.The test product 
appeared to be effective in reducing both pruritus and xerosis in he-
modialysis patients. It is very probable that the observed decrease 
of pruritus with the test product therapy was not only the result of 
dry skin improvement but that the addition of endocannabinoids 
may have also played a role. These preliminary results are encour-
aging, however, additional controlled studies are needed to clarify 
the exact usefulness of this product in therapy of uremic pruritus.   
KEY WORDS: uremic pruritus; xerosis; hemodialysis; endocan-
nabinoids 
INTRODUCTION
 Uremic pruritus is still a common phenomenon 
in patients with end-stage renal failure (1,2). It is re-
garded as one of the most bothersome symptoms 
in patients on maintenance hemodialysis. The 
etiopathogenesis of uremic itch remains unclear. 
Several theories and hypotheses have been pro-
posed, including dryness of the skin, mast cell ac-
cumulation, disturbance in tryptase and chymase 
activity, imbalance in divalent ions, peripheral neu-
ropathy and opioid system involvement (reviewed 
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in ref. 3). As the pathogenesis of this symptom has 
not yet been fully elucidated, there is no treatment 
of choice for these patients. Many treatment mo-
dalities have been tried to reduce uremic pruritus, 
however, the majority of them produced insufﬁ-
cient and only temporary improvement (reviewed 
in ref. 4). Therefore, every new therapeutic option 
for uremic pruritus is desirable. 
 This study was undertaken to evaluate the ef-
ﬁcacy of a cream with structured physiological 
lipids (DMS®, Derma Membrane Structure®) and 
endogenous cannabinoids in controlling pruritus 
in patients on maintenance hemodialysis, and to 
assess local tolerance and patient acceptability of 
the test product in the study population. Moreover, 
we evaluated the efﬁcacy of the tested cream for 
possible xerosis in chronic hemodialysis patients.
PATIENTS AND METHODS
Patients
 At the beginning 23 patients on maintenance 
hemodialysis suffering from uremic pruritus were 
included in the study. One patient refused to con-
tinue the trial just after one day of the test product 
application, without giving the reason for this (no 
adverse effects were observed). The next one died 
from slowly increasing hyperkaliemia two weeks 
of starting the trial. So, 21 patients (10 female and 
11 male) completed the trial. Their age ranged 
from 31 to 81, mean 58 years. They had been on 
hemodialysis for 0.5 to 17, mean 4.2 years. The 
reasons for chronic renal insufﬁciency in these pa-
tients were as follows: chronic glomerulonephritis 
(n=8), diabetic nephropathy (n=6), interstitial ne-
phritis (n=3), polycystic kidney disease (n=2) and 
nephropathy due to arterial hypertension (n=2). 
All patients were hemodialyzed 3 times a week 
for 4 hours using bicarbonate-based dialysate. 
Polysulphone membranes were used in 19 and 
cuprophane membranes in the remaining two pa-
tients. All patients suffered from uremic itch. The 
duration of pruritus varied from one month to 17 
years, mean 2.7 years. In six patients the inten-
sity of pruritus increased during the hemodialysis 
procedure, in one subject just after hemodialysis; 
in the remaining 14 patients the intensity of pru-
ritus did not depend on hemodialysis sessions. 
Seven patients had previously tried to reduce their 
pruritus using oral anihistaminics (n=6) or topical 
moderately potent corticosteroids (n=1), without 
any marked clinical improvement. None of the 
patients had used any antipruritic treatment such 
as emollients for at least 4 weeks before the trial. 
 Methods
 All patients underwent careful dermatologic 
examination to diagnose uremic pruritus. They all 
applied the cream with structured natural lipids 
(DMS®) containing endocannabinoids: N-acety-
lethanolamine (AEA) and N-palmitoylethanol-
amine (PEA) (Physiogel AI® cream) twice daily 
for a period of 3 weeks. Pruritus was evaluated 
by the same investigators using two pruritus scor-
ing methods: standard visual analog scale (VAS) 
and questionnaire method, successfully used by 
our group in several studies on different types of 
pruritus. This method consisted of the assessment 
of distribution, frequency and severity of pruritus, 
and sleep disturbances caused by itching. Details 
of this measurement are given in Table 1. More-
over, all patients had dry skin scored according to 
the 5-point scale, as follows:
0 smooth skin
1 patches of ﬁne, powdery scales
2 diffuse ashy appearance with ﬁne scales
3 moderate scaling with beginning cracks
4 intense scaling, moderate cracks
 The most dry skin area of the patient’s skin was 
selected for xerosis evaluation. Global pruritus 
and xerosis were examined before the trial as well 
as on study visits at weekly intervals and at the 
follow-up visit performed two weeks of discontinu-
ation of the cream application. Moreover, at the 
end of the cream usage (3 weeks of application) 
global tolerance was evaluated by the investiga-
tors using the following 4-point scale:
1 very good tolerance
2 good tolerance
3 poor tolerance
4 very poor tolerance
 At the same time, global agreement of the pa-




3 poorly satisfactory 
4 not satisfactory at all
Statistical analysis
 Statistical analysis was performed by use of 
Wilcoxon test and Spearman rank correlation test. 
Values of p less than 0.05 were considered statis-
tically signiﬁcant.
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 Both scales used for pruritus evaluation 
showed a signiﬁcant positive correlation (r=0.52; 
p=0.015). After 3-week therapy, pruritus was com-
pletely eliminated in eight (38.1%) patients. During 
the follow-up period, pruritus reappeared in two of 
these eight patients but disappeared in another 
two patients. Thus, at follow-up 14 days of therapy 
discontinuation eight (38.1%) patients were free 
from itch.
 Evaluation of pruritus by VAS showed signiﬁ-
cant reduction of pruritus scores during the test 
product application (Table 2, Fig. 1). Differences in 
the scores between each two visits were statisti-
cally signiﬁcant. At 14 days of therapy discontinua-
tion pruritus increased signiﬁcantly in comparison 
to the assessment made at the end of treatment, 
however, it was still signiﬁcantly less intensive 
than before the treatment.
 
 Similar results were observed when pruritus 
was evaluated by the questionnaire method (Ta-
ble 2, Fig. 2). Pruritus was signiﬁcantly reduced 
on each study visit during the 3-week treatment 
period, and increased 14 days after therapy dis-
continuation, however, the difference between day 
21 and follow-up visit was not signiﬁcant. The in-
tensity of pruritus at follow-up visit was still signiﬁ-
cantly lower compared to the beginning of the trial. 
Details of statistical analysis are given in Table 3. 
 Assessment of the elements of pruritus evalu-
ation (distribution, frequency and severity of pru-
ritus, and sleep disturbances) showed all study 
parameters to signiﬁcantly decrease during the 
treatment (Tables 2 and 3, Fig. 3). The scores for 
sleep disturbances were reduced at a slower rate 
than those for other parameters, and increased 
signiﬁcantly upon discontinuation of the test prod-
uct usage. This was not observed for the distribu-
tion, frequency and severity of pruritus scores.
 Xerosis was observed in all study patients. At 
the beginning of the study, there was no signiﬁ-
cant correlation between the intensity of dry skin 
and severity of pruritus as assessed by either 
scale (VAS: r=0.31, p=0.17; questionnaire: r=0.36, 
Table 1. Pruritus score scale
Evaluation        Points
Distribution 
 Single area involved   1
 Multiple sites of pruritus   2
 Generalized pruritus   3
Frequency
 Four short episodes (<10 min)   1
One long (>10 min)   1
(maximum 5 points)
Severity
 Pruritus without the need to scratch  1
 Pruritus with the need to scratch, but without 
 physical signs of excoriations  2
 Pruritus unrelieved by scratching, but without 
 excoriations    3
 Pruritus accompanied by excoriations 4
 Totally restless    5
Sleep disturbance
 Each episode of awakening due to pruritus 2 
 (maximum 6 points) 












































Xerosis 1.76±0.94 0.52±0.51 0.24±0.44 0.19±0.4 0.43±0.6
Figure 1. Pruritus scores during therapy (VAS, vi-
sual analog scale)
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p=0.11). The 3-week treatment period resulted in 
complete reduction of xerosis in 17 (81%) patients. 
Symptoms of dry skin reappeared in four patients 
14 days after the end of therapy, so at follow-up 
visit 13 (61.9%) patients still had smooth skin. 
 Xerosis scores were signiﬁcantly reduced 
throughout the study period (Tables 2 and 3, Fig. 
4). A marked reduction (statistically signiﬁcant) was 
observed between baseline and day 7 as well as 
between day 7 and day 14 of the evaluation. Upon 
completion of the trial, the scores for dry skin in-
creased, however, the difference between day 21 
(end of therapy) and follow-up visit did not reach 
statistical signiﬁcance. At follow-up visit xerosis 
remained signiﬁcantly less intensive compared to 
the beginning of the study.        
 The test product was very well tolerated by all 
patients (100%). Neither functional nor physical 
side effects were observed. 
 At the end of the study cream application, 11 
(52.4%) patients found the ﬁnal result of the treat-
ment to be satisfactory, eight (38.1%) patients con-
sidered it very satisfactory, and only two (9.5%) 
patients stated the therapeutic result to be only 
poorly satisfactory (Fig. 5).
 
DISCUSSION
 To the best of our knowledge, this is the ﬁrst 
study evaluating topical application of a prepara-
tion containing endocannabinoids in the treatment 
of uremic pruritus. In an open study, we demon-
strated that the preparation with structured natu-
ral lipids (DMS®) and endocannabinoids could 
be helpful in controlling itching and xerosis in pa-
tients on maintenance hemodialysis. However, 
as the pathogenesis of uremic pruritus is not fully 
known, the exact mechanism of antipruritic action 
of the tested cream could only be hypothesized. 
  One of the most important functions of healthy 
skin is to function as a barrier between the envi-
ronment and the body. This function can only be 
fulﬁlled by intactness of its lipid permeability bar-
rier, a unique stack of bilayers assembled in the 
epidermis from a mixture of biomolecules (5). In 
hemodialysis patients, the skin is dry because the 
Figure 2. Pruritus scores during therapy by the 
questionnaire method.
Table 3. Statistical analysis of  pruritus and xerosis scores during treatment
(1) vs. (2) (2) vs. (3) (3) vs. (4) (4) vs. (5) (1) vs. (4) (1) vs. (5)
Pruritus VAS p=0.0001 p=0.006 p<0.05 p=0.025 p<0.0001 p=0.0001
Questionnaire p=0.006 p=0.044 p=0.052 NS p<0.0001 p=0.0002
Distribution p=0.011 NS NS NS p=0.0005 p=0.0007
Frequency p=0.002 p=0.056 NS NS p=0.0007 p=0.0009
Severity p=0.0007 NS p<0.05 NS p=0.001 p=0.002
Sleep 
disturbances
NS NS NS p=0.04 p=0.01 NS
Xerosis p=0.0004 p=0.03 NS NS P=0.0001 p=0.0007
NS = nonsigniﬁcant
Figure 3. Elements of pruritus evaluation (ques-
tionnaire method) during therapy.
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Sleep disturbances Distribution Frequency Severity
reduced histamine-induced itch and vasodilata-
tion by applying them topically before the admin-
istration of histamine. In addition, coadministration 
of selective cannabinoid 1 receptor agonists with 
histamine markedly reduced the axon reﬂex ﬂare 
response (11). Moreover, PEA has been demon-
strated to down-modulate mast cell degranulation 
induced either by neurogenic (substance P) or im-
mune-mediated stimuli, both in vitro and in vivo 
(12,13). PEA also exerts a potent inhibitory effect 
on cytokines (interleukins 4, 6, 8) release from 
macrophages and peripheral blood mononuclear 
cells (14), and decreases the levels of tumor ne-
crosis factor α (TNF-α) during inﬂammation (15). 
It also inhibits nitric oxide macrophage production 
induced by lipopolysaccharide (16). Additionally, 
in the rat paw formalin-induced pain test PEA was 
able to activate an analgesic response (17). The 
results of clinical and histologic evaluation of PEA 
in cats with eosinophilic granuloma demonstrated 
that after one month of treatment, 64% of all ani-
mals given PEA showed improvement of pruritus, 
erythema and alopecia, and 67% revealed im-
provement of the extent and severity of the lesion 
(18). Moreover, treatment for 30 days with PEA 
signiﬁcantly increased densitometric values of cu-
taneous mast cells, suggesting that PEA is able to 
effectively decrease mast cell degranulation and 
increase intracellular concentration of mast cell 
granules. Finally, in cats with eosinophilic plaque, 
the clinical improvement directly correlated with 
the increase in mast cell densitometry and this 
correlation was highly signiﬁcant despite the small 
number of cases (18). All these ﬁndings could in-
dicate that endocannabinoids may bring relief in 
uremic pruritus per se, as several phenomena 
mentioned above (effect on mast cells, histamine 
and cytokines) could play a role in the pathogen-
esis of uremic pruritus. The anti-inﬂammatory and 
anti-nociceptive properties of endocannabinoids 
may possibly be responsible for their antipruritic 
effect (9,19). Mast cells could also be regarded 
lipid barrier is often damaged (3,4). This can result 
in intense itching in such patients. Some studies 
even showed a correlation between uremic pru-
ritus and intensity of xerosis (1). Therefore, it is 
reasonable to use emollients in this group of in-
dividuals, which was clearly mentioned in the re-
cent guidelines for controlling itching in systemic 
diseases (6). The majority of the skin-care prod-
ucts contain emulsiﬁers to disperse lipids in the 
formulation. These emulsiﬁers could damage or 
even destroy the continuous-bilayer structure in 
the skin. The preparation evaluated in the present 
study does not contain any emulsiﬁers, as it con-
tains a unique structure of active lipids similar to 
the lipids of stratum corneum, which are dispersed 
in the concentrate in a lamellar structure similar 
to the physiological structure of the lipids of the 
stratum corneum. Moreover, the active lipids are 
combined to classic ingredients with moisturizing 
properties. Such a formula could be responsible 
for the very good effect in the treatment of xero-
sis, as also demonstrated in other clinical studies 
(7,8).  
 Although the antipruritic action of the prepara-
tion evaluated could be related to the moisturizing 
effect of the tested cream, it is very likely that the 
pruritus reduction with the test product application 
was not only the result of dry skin improvement. 
At the beginning of the trial, there was no signiﬁ-
cant correlation between the intensity of xerosis 
and severity of pruritus in the study patients. We 
do believe that the ﬁnal result could have been in-
ﬂuenced by the additional ingredients of endocan-
nabinoids. The endocannabinoids (N-acetyletha-
nolamine – AEA and N-palmitoylethanolamine – 
PEA), which are normally found in the lipid fraction 
of rat brain, liver, skeletal muscle, paw skin and 
testis (9), could interact with the peripheral can-
nabinoid receptors. It has been shown that human 
keratinocytes partake in the peripheral endocan-
nabinoid system (10). Rukwied et al. (11) proved 
that cannabinoid receptor agonists signiﬁcantly 
Figure 4. Xerosis scores during therapy.
Figure 5. Patient assessment of therapy efficacy 
(pruritus reduction).
ACTA DERMATOVENEROLOGICA CROATICA
Szepietowski et al:    Acta Dermatovenerol Croat



















































as a target point of endocannabinods in reliev-
ing uremic pruritus, as several studies showed an 
increased mast cell density in patients suffering 
from uremic pruritus (20-23). Moreover, in these 
patients mast cells were mainly degranulated and 
dispersed throughout the skin. Additionally, trypt-
ase and chymase discrepancies were found in 
the skin of hemodialysis patients with uremic itch 
(20,21). 
 It is important to note that the majority of our 
patients considered the ﬁnal effect of the applied 
treatment satisfactory or very satisfactory in pruri-
tus reduction.   
 In conclusion, this preliminary clinical study 
suggested that the synergistic effect of the natural 
ingredients (essential fatty acids embedded into 
the Derma-Membrane-Structure® and the com-
position of endocannabinoids) may help restore 
typical skin reactions such as pruritus and xero-
sis in hemodialysis patients. However, additional 
controlled studies are needed to conﬁrm its useful-
ness in uremic itch and uremic xerosis.
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Nivea cream – for skin protection in housewives, chemical and laboratory technicians.
From the Nivea collection of Zlatko Puntijar (1928)
